Sanjeev Narula, the Chief Financial and Business Officer at Phathom Pharmaceuticals, Inc., has made a notable acquisition of company stock. According to a recent SEC filing, Narula acquired 13,485 shares of Phathom Pharmaceuticals at a price of $6.78 per share. This transaction occurred on October 6, 2026, and reflects Narula's ongoing commitment to the company.

This filing is significant as it underscores the importance of transparency in executive transactions, particularly within the pharmaceutical industry. Such disclosures are essential for maintaining investor confidence and ensuring that all stakeholders are informed about the financial activities of key executives.

Background

Phathom Pharmaceuticals, Inc. is a company engaged in the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. The company is incorporated in Delaware and has its business address in Florham Park, New Jersey. The firm's fiscal year ends on December 31. Narula's recent filing is part of a series of disclosures, with the latest being on October 8, 2026, where he reported his stock transaction.

What the Filing Says

The SEC filing, accession number 0001193125-26-418114, details that Narula acquired 13,485 shares of common stock, increasing his total holdings to 214,718 shares. The filing states, "Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation." Additionally, it notes that Narula has 1,123 shares held indirectly through a 401(k) plan.

Impact

This acquisition may influence the perception of Phathom Pharmaceuticals among investors and analysts. By increasing his stake in the company, Narula signals confidence in Phathom's future prospects. Such actions can have a ripple effect, potentially encouraging other executives and stakeholders to follow suit, thereby impacting the overall market sentiment towards the company.

What's Next

The filing does not say what happens next regarding Narula's stock ownership or any future transactions. However, continued scrutiny of executive transactions will likely remain a focus for investors and analysts in the pharmaceutical sector.